Fulgent Genetics Inc - ESG Rating & Company Profile powered by AI
The dashboard includes a Q&A table about Fulgent Genetics Inc. Alternative companies in the scoring industry group for Fulgent Genetics Inc are displayedin the table. The page displays a zero-cost E,S&G assessment covering Fulgent Genetics Inc.
Fulgent Genetics Inc in the Advanced Medical Equipment & Technology industry gained a UN SDG ESG Transparency Score of 1.3; made up of an environmental score of 1.3, social score of 0.0 and governance score of 2.7.
1.3
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Calmark Sweden AB | 8.0 | High |
1 | CHC Healthcare Group | 8.0 | High |
... | ... | ... | |
236 | Sisram Medical Ltd | 1.5 | Low |
239 | Progenity Inc | 1.4 | Low |
240 | Fulgent Genetics Inc | 1.3 | Low |
240 | Evolent Health Inc | 1.3 | Low |
240 | Feng Chi Biotech Corp | 1.3 | Low |
260 | Zhuhai Hokai Medical Instruments Co Ltd | 0.0 | Low |
260 | Zynex Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Fulgent Genetics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Fulgent Genetics Inc disclose current and historical energy intensity?
Does Fulgent Genetics Inc report the average age of the workforce?
Does Fulgent Genetics Inc reference operational or capital allocation in relation to climate change?
Does Fulgent Genetics Inc disclose its ethnicity pay gap?
Does Fulgent Genetics Inc disclose cybersecurity risks?
Does Fulgent Genetics Inc offer flexible work?
Does Fulgent Genetics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Fulgent Genetics Inc disclose the number of employees in R&D functions?
Does Fulgent Genetics Inc conduct supply chain audits?
Does Fulgent Genetics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Fulgent Genetics Inc conduct 360 degree staff reviews?
Does Fulgent Genetics Inc disclose the individual responsible for D&I?
Does Fulgent Genetics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Fulgent Genetics Inc disclose current and / or historical scope 2 emissions?
Does Fulgent Genetics Inc disclose water use targets?
Does Fulgent Genetics Inc have careers partnerships with academic institutions?
Did Fulgent Genetics Inc have a product recall in the last two years?
Does Fulgent Genetics Inc disclose incidents of discrimination?
Does Fulgent Genetics Inc allow for Work Councils/Collective Agreements to be formed?
Has Fulgent Genetics Inc issued a profit warning in the past 24 months?
Does Fulgent Genetics Inc disclose parental leave metrics?
Does Fulgent Genetics Inc disclose climate scenario or pathway analysis?
Does Fulgent Genetics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Fulgent Genetics Inc disclose the pay ratio of women to men?
Does Fulgent Genetics Inc support suppliers with sustainability related research and development?
Does Fulgent Genetics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Fulgent Genetics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Fulgent Genetics Inc involved in embryonic stem cell research?
Does Fulgent Genetics Inc disclose GHG and Air Emissions intensity?
Does Fulgent Genetics Inc disclose its waste policy?
Does Fulgent Genetics Inc report according to TCFD requirements?
Does Fulgent Genetics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Fulgent Genetics Inc disclose energy use targets?
Does Fulgent Genetics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Fulgent Genetics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Fulgent Genetics Inc
These potential risks are based on the size, segment and geographies of the company.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.